drugset / Trial / NCT03791905
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
RandomizedParallel-groupTriple-blindTreatment
Summary
Since multiple studies have demonstrated that PET can identify responders and non-responders to induction chemotherapy, using FDG-PET imaging to guide treatment decisions has prompted interest in clinical practice. The aim of this study was to evaluate whether changing chemotherapy regimen during radiation based on PET response to induction chemotherapy can improve clinical complete response (cCR) in patients with unresectable esophageal squamous cell carcinoma (ESCC).
Timeline
- Start
- 2019-01-15
- Primary completion
- 2021-07
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 150 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2 g | — |